688 related articles for article (PubMed ID: 23413807)
21. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Finkelstein Y; Soon GS; Acuna P; George M; Pope E; Ito S; Shear NH; Koren G; Shannon MW; Garcia-Bournissen F
Pediatrics; 2011 Oct; 128(4):723-8. PubMed ID: 21890829
[TBL] [Abstract][Full Text] [Related]
22. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
[TBL] [Abstract][Full Text] [Related]
23. A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption.
Anderson HJ; Lee JB
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577848
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
[TBL] [Abstract][Full Text] [Related]
25. Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review.
Mitre V; Applebaum DS; Albahrani Y; Hsu S
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469697
[TBL] [Abstract][Full Text] [Related]
26. Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China.
Sun J; Liu J; Gong QL; Ding GZ; Ma LW; Zhang LC; Lu Y
Drug Des Devel Ther; 2014; 8():2539-47. PubMed ID: 25548516
[TBL] [Abstract][Full Text] [Related]
27. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
28. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
29. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
Hosaka H; Ohtoshi S; Nakada T; Iijima M
J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
[TBL] [Abstract][Full Text] [Related]
30. [Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].
Saka B; Kombaté K; Mouhari-Toure A; Akakpo S; Tchangaï-Walla K; Pitché P
Med Trop (Mars); 2010 Jun; 70(3):255-8. PubMed ID: 20734593
[TBL] [Abstract][Full Text] [Related]
31. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
[TBL] [Abstract][Full Text] [Related]
32. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
[TBL] [Abstract][Full Text] [Related]
33. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience.
Nizamoglu M; Ward JA; Frew Q; Gerrish H; Martin N; Shaw A; Barnes D; Shelly O; Philp B; El-Muttardi N; Dziewulski P
Burns; 2018 May; 44(3):603-611. PubMed ID: 29029855
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and prognostic factors in severe cutaneous drug reactions.
Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU
Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402
[TBL] [Abstract][Full Text] [Related]
35. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
Halevy S
Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
[TBL] [Abstract][Full Text] [Related]
36. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
37. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
Murata J; Abe R; Shimizu H
J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
[TBL] [Abstract][Full Text] [Related]
38. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
[TBL] [Abstract][Full Text] [Related]
39. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy.
Mockenhaupt M
J Dtsch Dermatol Ges; 2009 Feb; 7(2):142-60; quiz 161-2. PubMed ID: 19371237
[TBL] [Abstract][Full Text] [Related]
40. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
